story of the week
Sorafenib Maintenance After Allogeneic HSCT in Patients With AML With FLT3 Internal Tandem Duplications
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Lancet Haematol 2023 Jul 03;[EPub Ahead of Print], L Xuan, Y Wang, K Yang, R Shao, F Huang, Z Fan, P Chi, Y Xu, N Xu, L Deng, X Li, X Liang, X Luo, P Shi, H Liu, Z Wang, L Jiang, R Lin, Y Chen, S Tu, Y Zhang, J Sun, X Huang, Q LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.